CymaBay Pipeline

Home / Pipeline / Additional Programs

Additional Programs

Our pipeline includes an additional program being evaluated for chronic diseases with high unmet medical needs.

MBX-2982: Targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action that acts directly on the beta cell to increase insulin secretion and stimulates release of the incretin GLP-1 from the gut. In recent preclinical studies (Nina Xiaoyan Li et al. Diabetes 2018;67:1401-1413), GPR119 agonists were shown to enhance glucagon secretion in response to low glucose levels and were able to prevent hypoglycemia in animal models.

Glucagon is a hormone secreted by the pancreas, that naturally reverses hypoglycemia by signaling the body to release stored glucose. This process is defective in individuals with insulin-dependent diabetes, such as Type 1 Diabetes (T1D). If left uncorrected, hypoglycemia can lead to unconsciousness or death. Preventing episodes of hypoglycemia in persons with diabetes is an unmet medical need. According to the 2016 global HAT study of 27,000 people, 4 out of 5 individuals with T1D reported hypoglycemia, with a rate of severe hypoglycemia (requiring assistance of another person) of approximately 5 events per patient-year.

We are providing MBX-2982 to the AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead a Phase 2a proof-of-pharmacology study to determine whether MBX-2982 can enhance glucagon secretion during insulin-induced hypoglycemia in subjects with T1D ( The study is funded by The Leona M. and Harry B. Helmsley Charitable Trust. The study will evaluate MBX-2982 for its ability to increase secretion of glucagon, a hormone that reverses low blood glucose levels (hypoglycemia) in individuals with T1D.

We have previously conducted clinical studies for MBX-2982 as a potential treatment for Type 2 Diabetes, demonstrating MBX-2982 was safe and well tolerated. CymaBay wholly owns and retains all rights to MBX-2982.